Navigation Links
Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain
Date:2/24/2009

CHICAGO Women who experience chest pain are sent to a cardiologist to go through a standard battery of tests, and often times test results show no evidence of coronary artery disease which is the most common cause of chest pain. This is a less common occurrence in men, and these women are sent home with little more than reassurance but often times return to their physicians complaining of similar symptoms and are more likely to develop future cardiac events.

To better determine the cause of difficult to diagnose chest pain among women, physicians at Northwestern Memorial's Bluhm Cardiovascular Institute are initiating a research study designed to identify the prevalence of a condition called Syndrome X. This disease process affects the endothelial function of blood vessels, a condition where the layers of the cells are not functioning properly and may be undetectable by standard testing such as exercise stress test and cardiac angiography. Researchers believe that endothelial dysfunction is the earliest stage of coronary artery disease. The goal of the study is to determine a more accurate diagnosis for women who present with chest pain symptoms and to determine if a more aggressive treatment regimen than the current standard of care may be adopted in the future.

In women there may be a different disease process which could be due to endothelial dysfunction, which is not something that can be detected by the current standard of care regimen. "Given that endothelial dysfunction may be an early stage of atherosclerosis, or fat deposits in the arteries, some have suggested medical treatment and lifestyle changes similar to those recommended to women with obstructive coronary artery disease," says Martha Gulati, MD, associate medical director of the Center for Women's Cardiovascular Health and assistant professor of medicine at Northwestern University's Feinberg School of Medicine.

"There are currently no other randomized trials comparing the effectiveness of such therapy in women with cardiac symptoms, normal coronary arteries but evidence of coronary endothelial dysfunction," commented Neil Stone, MD, medical director of the Center for Vascular Disease and professor of medicine at Northwestern University's Feinberg School of Medicine.

Study participants will undergo endothelial dysfunction testing, a procedure where medication is injected into the coronary arteries to directly assess endothelial response of the arteries, in order to identify women who may be likely to develop coronary artery disease and who would benefit from aggressive lifestyle and medical interventions. These interventions include dietary counseling, exercise, and medical treatment targeting improving the endothelial dysfunction.


'/>"/>

Contact: Amy Dobrozsi
adobrozs@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
2. Cardiologists Warn Proposed Changes Would Close Outpatient Cardiac Cath Labs
3. Cardiologists Spot Best Treatment for a Deadly Duo
4. Distinguished Cardiologists and Scientists Honored With 2008 International Academy of Cardiology Award
5. Dallas Cardiologists Explore Next Frontier in Vascular-Disease Treatments
6. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
7. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
8. Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the Ultimate Cardio Protection Against Heart Attacks, Strokes and Heart Failure.
9. Among Cardiologists, Women Cite Discrimination
10. Video: Cardiologists Recommend Lifestyle Habits for Healthy Hearts
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... , ... Gevir, a New Zealand-based company that focuses on developing powder and ... to Amazon.com, the world’s largest online retailer. , The company was founded ... natural treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at 28 years ...
(Date:2/22/2017)... ... 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches real ... Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate ... traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... with the recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at ... are common in auto accidents, product liability, premise liability and other personal injury cases. ...
(Date:2/22/2017)... ... ... ANGLESTRONG , the new recovery management app with multiple innovative features ... and Google Play . Florida-based Sober Network, Inc., the premier provider of ... Angle to build ANGLESTRONG. The new recovery management app is a passion project for ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... communications company, launched a new media platform connecting healthcare technology professionals and other ... be followed by a quarterly publication starting on March 1, announced Michael J. ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Research and Markets has ... by Drug Molecule (Biologic, Small Molecule Drugs), By Route of ... Blockers) Outlook 2022" report to their offering. ... The global psoriasis ... 2016-2022 This report provides a detailed analysis of ...
(Date:2/22/2017)... 2017  Based on its recent analysis of ... recognizes SnooZeal, Inc. with the 2017 European New ... product that intelligently addresses the root causes of ... the clinically proven continuous transmucosal electrical stimulation therapy. ... one of the most accessible anti-snoring products available ...
(Date:2/22/2017)... Feb. 22, 2017  Applied Silver, the maker of SilvaClean®, ... the company,s advisory board. Ms. Barnes is the company,s third ... engineering, legal, and healthcare experts Scott McNealy , ... , J. Tress Ritter , and Leopold Selker ... brings more than three decades of nationally recognized clinical, nursing, ...
Breaking Medicine Technology: